Recruiting
Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
ClinicalTrials.gov IDNCT04985058
PhaseNot Applicable
Enrollment108
SponsorHellenic Cooperative Oncology Group
Age18 Years
SexALL
Conditions studied
Breast Cancer
About this study
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
Primary outcomes
- Progression-free survival (Through the completion of the study, for an average of 6 months)
Eligibility information
Inclusion Criteria:
* Histologically confirmed HR-positive, HER2-negative breast cancer
* Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
* 18 years or older
* Any menopausal status
* Treatment with abemaciclib in combination with endocrine therapy
* Any endocrine therapy
* At least two months of treatment with abemaciclib
Study locations
- Hellenic Oncology Cooperative Group, Athens, Greece
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.